Tumor-infiltrating lymphocyte (TIL) therapy in combination with high-dose interleukin-2 (IL-2) should be considered as a second-line treatment of choice for patients with advanced melanoma who have received anti-PD-(L)1 therapy, according to researchers.
2024
BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma
BioNTech has announced positive topline findings from an ongoing phase 2 trial (NCT04526899) evaluating the investigational mRNA cancer immunotherapy BNT111 in combination with cemiplimab (Libtayo) for patients with unresectable stage III or IV melanoma who experienced disease progression following anti-PD-(L)1 therapy.
Sun exposure is driving rise in most melanoma cases
Doctors are diagnosing more people with melanoma.
Immunotherapy combination improves response in unresectable melanoma
An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.